Breaking News
Get 40% Off 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did. Read how
Close

Cellectis SA (CLLS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cellectis's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.060 -0.180    -5.56%
- Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 131,617
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 3.000 - 3.270
Cellectis 3.060 -0.180 -5.56%

Cellectis SA Company Profile

 
Get an in-depth profile of Cellectis SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

234

Equity Type

ADR

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Contact Information

Address 8, rue de la Croix Jarry
Paris, 75013
France
Phone 33 1 81 69 16 00
Fax 33 1 81 69 16 06

Top Executives

Name Age Since Title
Andre Choulika 58 1999 Co-Founder, CEO & Director
Jean-Pierre Garnier 76 2020 Independent Non-Executive Chairman
Marcela V. Maus 46 2017 Member of Clinical Advisory Board
Ghulam J. Mufti - - Member of Clinical Advisory Board
Dietger Niederwieser - 2017 Member of Clinical Advisory Board
Ola Landgren - 2017 Member of Clinical Advisory Board
Kanti Rai - 2017 Member of Clinical Advisory Board
Catherine Bollard 54 2017 Member of Clinical Advisory Board
Stephan A. Grupp - 2018 Member of Clinical Advisory Board
David J. D. Sourdive 56 2000 Deputy CEO, Executive VP of CMC & Manufacturing and Director
Laurent Arthaud 60 2011 Director
Marc Dunoyer 72 2023 Director
Tyrell Rivers 51 2023 Director
Pierre Bastid 70 2011 Independent Director
Donald A. Bergstrom 52 2021 Independent Director
Rainer J. Boehm 64 2017 Independent Director
Axel-Sven Malkomes 57 2022 Independent Director
Cecile Chartier 57 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CLLS Comments

Write your thoughts about Cellectis SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Marcel Demers
Marcel Demers Feb 03, 2023 11:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Is management trying to make this a penny stock?
Marcel Demers
Marcel Demers Feb 03, 2023 11:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Would have been nice if they cut this deal back when the stock was in the teens. At least this might stop the bleed
Ozgur Sari
Ozgur Sari Feb 18, 2022 1:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does anyone know why this is down so much?
Eren Eren
Eren Eren Feb 16, 2022 1:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is insane. Trading at cash right now.
Joel Hanson
Joel Hanson Nov 18, 2016 11:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
All 7 analyst covering say "buy" with an average 12 month target price of $47.16. That's 161% ROI at it's current price of $18.08.
Eren Eren
Eren Eren Nov 18, 2016 11:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Look where we are now 5 $
Eren Eren
Eren Eren Nov 18, 2016 11:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
3.5
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email